Morgan Stanley Has Lowered Expectations for IQVIA (NYSE:IQV) Stock Price

IQVIA (NYSE:IQV) had its price objective lowered by Morgan Stanley from $280.00 to $265.00 in a research report released on Monday morning,Benzinga reports. Morgan Stanley currently has an overweight rating on the medical research company’s stock.

A number of other brokerages have also recently commented on IQV. Deutsche Bank Aktiengesellschaft reduced their target price on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research report on Friday, November 1st. The Goldman Sachs Group cut their price objective on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a report on Friday, November 1st. Evercore ISI lowered their target price on IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Robert W. Baird cut their price target on IQVIA from $256.00 to $223.00 and set a “neutral” rating for the company in a report on Friday, November 1st. Finally, Jefferies Financial Group lowered IQVIA from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $266.00 to $242.00 in a research note on Wednesday, July 24th. Five analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $259.13.

IQVIA Stock Down 1.6 %

IQV opened at $217.68 on Monday. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA has a twelve month low of $190.20 and a twelve month high of $261.73. The company has a market cap of $39.51 billion, a PE ratio of 28.57, a price-to-earnings-growth ratio of 2.15 and a beta of 1.51. The company has a 50-day moving average price of $232.31 and a 200 day moving average price of $229.48.

Insiders Place Their Bets

In related news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the sale, the insider now owns 19,536 shares of the company’s stock, valued at $4,812,302.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in IQV. Versant Capital Management Inc lifted its stake in IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after buying an additional 110 shares during the last quarter. Opal Wealth Advisors LLC purchased a new position in shares of IQVIA during the second quarter worth approximately $27,000. Capital Performance Advisors LLP purchased a new stake in IQVIA in the 3rd quarter valued at $27,000. Park Place Capital Corp acquired a new stake in IQVIA during the 3rd quarter worth $28,000. Finally, Itau Unibanco Holding S.A. purchased a new position in IQVIA during the 2nd quarter worth $29,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.